top of page
Search

When Eating Feels Like a Minefield: A Story of MCAS, Ketotifen, and Low-Dose Naltrexone

When Eating Feels Like a Minefield: A Story of MCAS, Ketotifen, and Low-Dose Naltrexone

By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician


🎥 Watch the short version: MCAS, Ketotifen & LDN — a client story




For people living with mast cell activation syndrome (MCAS), eating can feel like a minefield. A food that was fine last month triggers flushing, hives, gut pain, or brain fog today. Over time, many people respond the only way that feels safe: they eliminate. First the obvious triggers, then the suspicious ones, then anything uncertain — until the "safe list" has shrunk to a handful of foods and mealtimes are ruled by fear rather than nourishment.


I want to share a story from my practice about how the right combination — introduced slowly and carefully — made a remarkable difference for one client. And, just as importantly, what that story does and doesn't mean for anyone else navigating MCAS.

A Shrinking Plate

One of my clients with MCAS had become extremely limited in the foods they could tolerate. This is one of the most distressing places an MCAS journey can lead. Beyond the nutritional concerns, there is a psychological weight to it: every meal becomes a risk calculation, social eating disappears, and the world gets smaller.


When someone arrives at this point, my goal is never to find a miracle. It is to find traction — some stabilization of the mast cell system that gives the body room to expand again.

The Combination: Ketotifen + LDN

For this client, we carefully introduced two medications together:


Compounded ketotifen. Ketotifen is an older antihistamine with a second, less widely known property: it acts as a mast cell stabilizer, helping to reduce the release of histamine and other inflammatory mediators at the source rather than just blocking their effects downstream (Grant et al., 1990). In the United States it is not commercially available as an oral tablet, so it is typically prepared by a compounding pharmacy, which also allows very gradual dose titration — something MCAS clients often need.


Low-dose naltrexone (LDN). At low doses, naltrexone appears to act quite differently than at standard doses, modulating glial cells and inflammatory signaling in ways that have made it a subject of growing interest for chronic inflammatory and pain conditions (Younger, Parkitny & McLain, 2014). In my practice, LDN has been a foundational tool for many clients with MCAS, autoimmunity, and chronic pain — always started low and adjusted patiently.


The result for this client? Over time, they were able to tolerate a much wider variety of foods. Meals stopped being a minefield and started being meals again.

The Important Part: There Is No Universal Protocol

Here is what I most want readers to take from this story — and it is not "ketotifen plus LDN treats MCAS."


MCAS treatment is highly individualized. The condition itself is heterogeneous: mast cells can misbehave in different ways in different people, and triggers, mediators, and comorbidities vary enormously from one person to the next (Molderings et al., 2011). There is no single medication, dose, or protocol that works for everyone. What produced a breakthrough for this client may do little for another — and something entirely different may be that person's key.


In my experience, progress in MCAS usually comes from a few unglamorous principles:


  • Go slowly. Start one change at a time, at low doses, so the body — and the clinician — can tell what is actually happening.

  • Adjust carefully. Titration in MCAS is a craft. Sensitive systems often need smaller steps than standard dosing guides suggest.

  • Let the body vote. Symptom response, not protocol adherence, guides the next step.

  • Expand, don't just restrict. The goal of stabilization is to widen the safe list again — restriction is a temporary shelter, not a destination.

Why This Is Personal

After years of seeing MCAS both personally and professionally, I've learned that individualized care matters enormously. Behind every shrinking food list is a person who has usually been dismissed, misdiagnosed, or told their symptoms don't fit a pattern. They fit a pattern — just not a common one. Taking that pattern seriously, and working through it one careful step at a time, is where recovery begins.

References

  1. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40(3):412–448.

  2. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451–459.

  3. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology & Oncology. 2011;4:10.





Important: This article is for educational purposes only and does not constitute medical advice. MCAS is a complex condition, and treatment decisions — including the use of ketotifen or low-dose naltrexone — should always be made in partnership with a qualified healthcare professional who knows your individual situation.




About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative medicine. He completed his fellowship training under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine as well as certifications in medical acupuncture and integrative & holistic medicine. He specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. Dr. Kim is the author of three books and more than 20 peer-reviewed articles.






Yoon Hang Kim MD | www.directintegrativecare.com | 📞 (210) 981-6106


Follow for more on MCAS, low-dose naltrexone, functional medicine, and integrative medicine.



 
 
 

Comments

bottom of page